Reclast (Zoledronic Acid) vs Prolia (Denosumab): Side-Effect Profile Head-to-Head

How These Two Drugs Work Differently

Reclast and Prolia both reduce bone resorption, but they do so through entirely different mechanisms, and those mechanisms explain their distinct side-effect profiles. Understanding this pharmacologic difference is the first step to predicting which adverse events matter for a given patient.

Reclast: A Bisphosphonate That Embeds in Bone

Zoledronic acid is a nitrogen-containing bisphosphonate that binds directly to hydroxyapatite in bone mineral. Once incorporated, it inhibits farnesyl pyrophosphate synthase inside osteoclasts, triggering osteoclast apoptosis 1. The drug accumulates in bone over successive doses and remains detectable for years after the last infusion. This long skeletal half-life means residual antiresorptive activity persists well beyond the dosing interval. Patients who stop Reclast do not experience a rapid surge in bone turnover.

Prolia: A Monoclonal Antibody That Blocks RANKL

Denosumab is a fully human monoclonal antibody targeting RANK ligand. It circulates in serum, preventing RANKL from activating osteoclasts 2. Because Prolia does not incorporate into bone matrix, its effect is completely reversible. Serum denosumab levels become undetectable approximately 6 months after the last injection, and bone turnover markers can rebound above baseline within weeks of that clearance. This on-off pharmacology is the root cause of Prolia's most concerning safety signal: rebound vertebral fractures after discontinuation.

Acute-Phase Reactions: Reclast's Signature Side Effect

The most common complaint with Reclast is the acute-phase reaction (APR), a flu-like syndrome of fever, myalgia, headache, and arthralgia occurring within the first 3 days after infusion. This is the side effect that most often drives patient dissatisfaction with zoledronic acid.

Incidence and Timing

In HORIZON-PFT (N=7,765), approximately 32% of patients experienced an APR after the first infusion 1. Symptoms peaked at 24 to 48 hours and typically resolved within 3 days. By the second annual infusion, the rate dropped to roughly 7%, and it continued to decline with each subsequent dose. Pre-treatment with acetaminophen or ibuprofen reduces symptom severity, according to a 2011 study in the Journal of Bone and Mineral Research (N=416) that showed acetaminophen 650 mg given before and for 72 hours after infusion cut APR incidence by about 40% 3.

Why Prolia Doesn't Cause APR

Denosumab does not trigger the same cytokine release that bisphosphonates provoke. In FREEDOM (N=7,868), rates of influenza-like illness, fever, and myalgia were comparable between denosumab and placebo groups 2. This difference alone makes Prolia the more comfortable drug in the short term. Patients who cannot tolerate Reclast's post-infusion symptoms often transition to denosumab for this reason.

Rebound Vertebral Fractures: Prolia's Unique Risk

No discussion of Prolia's safety profile is complete without addressing what happens when the drug is stopped. This is the single most important clinical distinction between the two agents from a safety standpoint.

The Discontinuation Problem

After stopping denosumab, bone turnover markers rise rapidly above pre-treatment levels, and BMD gains are lost within 12 to 24 months. Multiple case series documented clusters of multiple vertebral fractures occurring 7 to 16 months after the last Prolia dose. A 2017 analysis of the FREEDOM extension trial found that among patients who discontinued denosumab, the vertebral fracture rate returned to the level expected in untreated patients, and a subset experienced multiple vertebral fractures 4. The European Medicines Agency issued a warning in 2017. The FDA followed with updated labeling.

How Clinicians Manage This Risk

Current guidance from the American Society for Bone and Mineral Research (ASBMR) recommends that patients who stop Prolia transition to a bisphosphonate (oral or IV) to prevent rebound bone loss 5. One common protocol involves giving a single dose of zoledronic acid 6 months after the last denosumab injection. This "off-ramp" strategy is now standard practice.

Reclast does not carry this risk. Because zoledronic acid binds to bone for years, patients who stop treatment retain residual antiresorptive effect. A drug holiday of 3 to 6 years after 3 annual infusions is a recognized strategy endorsed by the ASBMR 5.

Infection Risk

Prolia's mechanism of RANKL inhibition extends beyond bone. RANKL plays a role in immune cell function, and this has raised questions about infection susceptibility.

Prolia and Infections in FREEDOM

In the FREEDOM trial, serious infections requiring hospitalization occurred in 4.1% of denosumab-treated patients vs. 3.4% in placebo, though this did not reach statistical significance (P=0.14) 2. Skin infections (cellulitis, erysipelas) were specifically noted in post-marketing surveillance. The FDA label for Prolia includes warnings about serious skin infections, and clinicians are advised to monitor patients with concurrent immunosuppressive therapy.

Reclast and Infections

Zoledronic acid has not been associated with increased infection risk. The HORIZON-PFT data showed no signal for cellulitis or other serious infections 1. Bisphosphonates do not interact with the RANKL/RANK immune axis in the same way.

Osteonecrosis of the Jaw (ONJ)

ONJ is the adverse event that generates the most patient anxiety for both drugs. The actual risk at osteoporosis doses is very low.

Incidence Data

In osteoporosis treatment populations, ONJ occurs at a rate of approximately 1 to 10 per 100,000 patient-years for both zoledronic acid and denosumab 6. This is orders of magnitude lower than the rates seen in oncology patients receiving much higher doses (e.g., zoledronic acid 4 mg monthly for bone metastases). The 2022 ASBMR task force position paper reaffirmed that the absolute risk of ONJ at osteoporosis doses is "very low" and should not deter treatment in patients with high fracture risk 5.

Risk Factors Worth Screening

Risk factors include invasive dental procedures, poor oral hygiene, glucocorticoid use, diabetes, and smoking. A dental evaluation before starting either drug is recommended but not mandatory per current guidelines. Neither drug appears to carry a definitively higher ONJ risk than the other at osteoporosis doses.

Atypical Femoral Fractures (AFF)

Both classes of antiresorptive therapy are associated with atypical subtrochanteric or diaphyseal femoral fractures. These are stress fractures that develop in the lateral femoral cortex, often preceded by prodromal thigh pain.

Duration-Dependent Risk

AFF risk increases with duration of bisphosphonate use beyond 5 years. A large Kaiser Permanente cohort study (N=196,129) found that AFF risk rose from 2 per 100,000 patient-years at 2 years of bisphosphonate use to 78 per 100,000 at 8+ years 7. For denosumab, post-marketing AFF cases have been reported, but the incidence appears similarly low. The FREEDOM extension (10-year data) reported only 2 confirmed AFF cases among 4,550 patients 8.

Clinical Takeaway

Both drugs carry this risk. Drug holidays for bisphosphonates after 3 to 5 years of treatment help mitigate AFF accumulation. For denosumab, the inability to take a true drug holiday (due to rebound risk) means AFF surveillance should continue for the entire treatment duration.

Hypocalcemia

Both drugs suppress osteoclast activity, which can lower serum calcium. The clinical significance differs.

Prolia's Greater Hypocalcemia Signal

Denosumab produces a more profound and rapid suppression of bone resorption compared to bisphosphonates. In FREEDOM, hypocalcemia was reported in 0.4% of denosumab patients vs. 0.1% of placebo 2. Patients with chronic kidney disease (CKD stage 4-5) are at particular risk. The Prolia label carries a boxed-adjacent warning about severe symptomatic hypocalcemia in patients with renal impairment. Calcium and vitamin D supplementation are required before and during treatment.

Reclast and Renal Considerations

Zoledronic acid is contraindicated in patients with creatinine clearance <35 mL/min due to nephrotoxicity risk, not hypocalcemia. The drug is cleared renally, and acute kidney injury has been reported with overly rapid infusion rates. The minimum recommended infusion time is 15 minutes. Transient increases in serum creatinine occurred in 1.2% of Reclast patients vs. 0.4% of placebo in HORIZON-PFT 1.

This creates a clinical fork: patients with moderate-to-severe CKD may be candidates for neither drug without nephrology consultation, though denosumab is not renally cleared and can be used cautiously in CKD with close calcium monitoring.

Musculoskeletal Pain

Both drugs list musculoskeletal pain as a side effect, but the patterns differ.

Reclast-associated bone, joint, and muscle pain is most often part of the acute-phase reaction and resolves within days. Rare cases of severe, prolonged musculoskeletal pain (lasting months) have been reported with bisphosphonates, prompting an FDA safety communication in 2008 9.

Prolia-associated musculoskeletal pain in FREEDOM occurred in 7.6% of denosumab patients vs. 6.8% of placebo. Back pain was reported in 34.7% vs. 34.6%, essentially identical to placebo 2. These rates suggest that chronic musculoskeletal complaints attributed to Prolia may often reflect underlying disease rather than drug effect.

Cardiovascular Events: Atrial Fibrillation

In HORIZON-PFT, serious atrial fibrillation occurred in 1.3% of zoledronic acid patients vs. 0.5% of placebo (P<0.001) 1. This signal prompted considerable investigation. A 2012 meta-analysis of bisphosphonate trials found no consistent association between bisphosphonate use and atrial fibrillation across the class 10. The FDA concluded that the evidence did not support a causal relationship, but the signal has not been fully explained.

Denosumab has not shown an atrial fibrillation signal. In FREEDOM, cardiovascular event rates were balanced between groups 2.

Who Tolerates Which Drug Better?

There is no single answer. Patient selection depends on the side-effect profile that matters most for the individual.

Reclast May Be Preferred When

Patients need a defined treatment duration with a clear drug holiday endpoint. Those who are reliable for annual clinic visits but not for biannual injections. Patients concerned about rebound fracture risk.

Prolia May Be Preferred When

Patients cannot tolerate the acute-phase reaction from Reclast. Those with renal impairment where zoledronic acid is contraindicated (CrCl <35). Patients already receiving subcutaneous medications who prefer a quick injection over an IV infusion.

Dr. Clifford Rosen, a senior scientist at Maine Medical Center Research Institute and author of the NEJM editorial accompanying the FREEDOM trial, noted: "The choice between a bisphosphonate and denosumab often comes down to the exit strategy. With bisphosphonates, you can stop. With denosumab, you need a plan for what comes next" 2.

The 2022 Endocrine Society clinical practice guideline states: "For patients at very high fracture risk, either zoledronic acid or denosumab is appropriate as initial therapy. The decision should incorporate patient preference, comorbidities, and a long-term treatment plan that accounts for discontinuation" 11.

Side-Effect Summary Table

| Side Effect | Reclast (Zoledronic Acid) | Prolia (Denosumab) | |---|---|---| | Acute-phase reaction | ~32% first dose | Not observed | | Rebound fractures on stopping | No | Yes (vertebral) | | ONJ (osteoporosis doses) | ~1-10/100,000 pt-yr | ~1-10/100,000 pt-yr | | Atypical femoral fracture | Rare, duration-dependent | Rare | | Hypocalcemia | Mild, infrequent | More clinically significant | | Renal toxicity | Contraindicated if CrCl <35 | Not renally cleared | | Serious infection | No signal | Small non-significant increase | | Atrial fibrillation | Possible signal (1.3% vs 0.5%) | No signal | | Musculoskeletal pain | APR-related, usually transient | Similar to placebo |

Reclast's acute-phase reaction rate drops from 32% after the first infusion to under 7% by the third annual dose, with acetaminophen pre-treatment reducing severity by approximately 40% 3.